• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

潜在变量建模及其对机构审查委员会审查的影响:延迟审查过程的变量

Latent variable modeling and its implications for institutional review board review: variables that delay the reviewing process.

作者信息

Tzeng Dong-Sheng, Wu Yi-Chang, Hsu Jane-Yi

机构信息

Kaohsiung Armed Forces General Hospital, No. 2, Chung-Cheng 1st Road, Kaohsiung City, Taiwan.

Tri-Service General Hospital Beitou Branch, Taipei City, Taiwan.

出版信息

BMC Med Ethics. 2015 Aug 27;16:57. doi: 10.1186/s12910-015-0050-8.

DOI:10.1186/s12910-015-0050-8
PMID:26311634
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4551705/
Abstract

BACKGROUND

To investigate the factors related to approval after review by an Institutional Review Board (IRB), the structure equation model was used to analyze the latent variables 'investigators', 'vulnerability' and 'review process' for 221 proposals submitted to our IRB.

METHODS

The vulnerability factor included vulnerable cases, and studies that involved drug tests and genetic analyses. The principal investigator (PI) factor included the license level of the PI and whether they belonged to our institution. The review factor included administration time, total review time, and revision frequency. The revision frequency and total review time influenced the efficiency of review.

RESULTS

The latent variable of reviewing was the most important factor mediating the PIs and vulnerability to IRB review approval. The local PIs moderated with genetic study and revision frequency had an impact on the review process and mediated non-approval.

CONCLUSIONS

Better guidance of the investigators and reviewers might improve the efficiency with which IRBs function.

摘要

背景

为了调查与机构审查委员会(IRB)审查后批准相关的因素,采用结构方程模型分析了提交给我们IRB的221份提案的潜在变量“研究者”、“脆弱性”和“审查过程”。

方法

脆弱性因素包括脆弱案例以及涉及药物测试和基因分析的研究。主要研究者(PI)因素包括PI的执照级别以及他们是否隶属于我们的机构。审查因素包括管理时间、总审查时间和修订频率。修订频率和总审查时间影响审查效率。

结果

审查的潜在变量是介导PI与IRB审查批准的脆弱性之间关系的最重要因素。当地PI与基因研究的调节作用以及修订频率对审查过程有影响并介导不批准。

结论

对研究者和审查者进行更好的指导可能会提高IRB的运作效率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73cf/4551705/a7d467a1a2b3/12910_2015_50_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73cf/4551705/1476cd683791/12910_2015_50_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73cf/4551705/a7d467a1a2b3/12910_2015_50_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73cf/4551705/1476cd683791/12910_2015_50_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73cf/4551705/a7d467a1a2b3/12910_2015_50_Fig2_HTML.jpg

相似文献

1
Latent variable modeling and its implications for institutional review board review: variables that delay the reviewing process.潜在变量建模及其对机构审查委员会审查的影响:延迟审查过程的变量
BMC Med Ethics. 2015 Aug 27;16:57. doi: 10.1186/s12910-015-0050-8.
2
The Impact of Institutional Review Boards (IRBs) on Clinical Innovation: A Survey of Investigators and IRB Members.机构审查委员会(IRB)对临床创新的影响:对研究者和IRB成员的一项调查
J Empir Res Hum Res Ethics. 2015 Dec;10(5):481-7. doi: 10.1177/1556264615614936.
3
American Society of Clinical Oncology policy statement: oversight of clinical research.美国临床肿瘤学会政策声明:临床研究监督
J Clin Oncol. 2003 Jun 15;21(12):2377-86. doi: 10.1200/JCO.2003.04.026. Epub 2003 Apr 29.
4
The Real-Time IRB: A Collaborative Innovation to Decrease IRB Review Time.实时机构审查委员会:一项减少机构审查委员会审查时间的合作创新。
J Empir Res Hum Res Ethics. 2018 Oct;13(4):432-437. doi: 10.1177/1556264618780803. Epub 2018 Jun 14.
5
Understanding institutional review boards: practical guidance to the IRB review process.了解机构审查委员会:IRB审查过程实用指南
Nutr Clin Pract. 2007 Dec;22(6):618-28. doi: 10.1177/0115426507022006618.
6
Costs and inconsistencies in US IRB review of low-risk medical education research.美国机构审查委员会对低风险医学教育研究审查的成本及不一致性
Med Educ. 2015 Jun;49(6):634-7. doi: 10.1111/medu.12693.
7
Ethical standards for medical research in the Israeli military - review of the changes in the last decade.以色列军队医学研究的伦理标准——过去十年变化回顾
Isr J Health Policy Res. 2016 Dec 1;5:53. doi: 10.1186/s13584-016-0113-4. eCollection 2016.
8
Operational Characteristics of Institutional Review Boards (IRBs) in the United States.美国机构审查委员会(IRB)的运作特点
AJOB Empir Bioeth. 2019 Oct-Dec;10(4):276-286. doi: 10.1080/23294515.2019.1670276. Epub 2019 Oct 16.
9
Is your ethics committee efficient? Using "IRB Metrics" as a self-assessment tool for continuous improvement at the Faculty of Tropical Medicine, Mahidol University, Thailand.你的伦理委员会高效吗?使用“机构审查委员会指标”作为泰国玛希隆大学热带医学院持续改进的自我评估工具。
PLoS One. 2014 Nov 18;9(11):e113356. doi: 10.1371/journal.pone.0113356. eCollection 2014.
10
Should society allow research ethics boards to be run as for-profit enterprises?社会应该允许研究伦理委员会作为营利性企业来运作吗?
PLoS Med. 2006 Jul;3(7):e309. doi: 10.1371/journal.pmed.0030309. Epub 2006 Jul 25.

引用本文的文献

1
A personalized Institutional Review Board Liaison Service: Evaluation over its initial 30 months.一项个性化的机构审查委员会联络服务:对其最初30个月的评估
Int J Acad Med. 2020 Apr-Jun;6(2):96-102. Epub 2020 Jun 29.
2
The IRB structure and medical research reform.机构审查委员会的结构与医学研究改革。
Clin Transl Med. 2018 Apr 2;7(1):10. doi: 10.1186/s40169-018-0188-3.
3
Effects of Regulatory Support Services on Institutional Review Board Turnaround Times.监管支持服务对机构审查委员会周转时间的影响。

本文引用的文献

1
Variations in institutional review board approval in the implementation of an improvement research study.改进研究实施过程中机构审查委员会批准情况的差异。
Nurs Res Pract. 2013;2013:548591. doi: 10.1155/2013/548591. Epub 2013 Apr 23.
2
Institutional review board barriers and solutions encountered in the Collaboration Among Pharmacists and Physicians to Improve Outcomes Now Study: a national multicenter practice-based implementation trial.药剂师与医生合作改善结果研究(“改善结果现在”研究)中遇到的机构审查委员会障碍及解决方案:一项基于全国多中心实践的实施试验
Pharmacotherapy. 2013 Sep;33(9):902-11. doi: 10.1002/phar.1276. Epub 2013 May 3.
3
J Empir Res Hum Res Ethics. 2017 Jul;12(3):131-139. doi: 10.1177/1556264617704294. Epub 2017 Apr 16.
Individual genetic and genomic research results and the tradition of informed consent: exploring US review board guidance.
个体遗传和基因组研究结果与知情同意传统:探索美国审查委员会的指导意见。
J Med Ethics. 2012 Jul;38(7):417-22. doi: 10.1136/medethics-2011-100273. Epub 2012 Mar 5.
4
Genetics researchers' and IRB professionals' attitudes toward genetic research review: a comparative analysis.遗传研究人员和 IRB 专业人员对遗传研究审查的态度:比较分析。
Genet Med. 2012 Feb;14(2):236-42. doi: 10.1038/gim.2011.57. Epub 2012 Jan 12.
5
Burdens on research imposed by institutional review boards: the state of the evidence and its implications for regulatory reform.机构审查委员会给研究带来的负担:证据现状及其对监管改革的影响。
Milbank Q. 2011 Dec;89(4):599-627. doi: 10.1111/j.1468-0009.2011.00644.x.
6
Ethical issues posed by cluster randomized trials in health research.健康研究中群组随机试验引发的伦理问题。
Trials. 2011 Apr 20;12:100. doi: 10.1186/1745-6215-12-100.
7
A systematic review of the empirical literature evaluating IRBs: what we know and what we still need to learn.对评估机构审查委员会的实证文献进行的系统综述:我们已知的和仍需了解的内容。
J Empir Res Hum Res Ethics. 2011 Mar;6(1):3-19. doi: 10.1525/jer.2011.6.1.3.
8
Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate.向机构审查委员会报告严重药品不良事件的质量:以新型抗癌药物甲磺酸伊马替尼为例的案例研究
Clin Cancer Res. 2009 Jun 1;15(11):3850-5. doi: 10.1158/1078-0432.CCR-08-1811. Epub 2009 May 19.
9
Density of cerebellar basket and stellate cells in autism: evidence for a late developmental loss of Purkinje cells.自闭症中小脑篮状细胞和星状细胞的密度:浦肯野细胞发育后期丢失的证据。
J Neurosci Res. 2009 Aug 1;87(10):2245-54. doi: 10.1002/jnr.22056.
10
Pacemaker therapy for early and late sinus node dysfunction in orthotopic heart transplant recipients: a single-center experience.心脏原位移植受者早期和晚期窦房结功能障碍的起搏器治疗:单中心经验
Pacing Clin Electrophysiol. 2008 Sep;31(9):1108-12. doi: 10.1111/j.1540-8159.2008.01149.x.